These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10670791)

  • 1. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery.
    Matsubayashi K; Ueda Y; Ogino H; Sugita T; Sakakibara Y; Matsuyama K; Nomoto T
    Thorac Cardiovasc Surg; 1999 Dec; 47(6):352-6. PubMed ID: 10670791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of docarpamine on hemodynamics after open heart surgery in children.
    Watarida S; Shiraishi S; Sugita T; Katsuyama K; Nakajima Y; Yamamoto R; Yamamoto Y; Imura M; Hirokawa R; Mori A
    Ann Thorac Cardiovasc Surg; 2000 Apr; 6(2):106-9. PubMed ID: 10870004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery.
    Tano K; Yoshizumi M; Kitagawa T; Hori T; Kitaichi T; Itoh K; Katoh I
    Life Sci; 1997; 61(15):1469-78. PubMed ID: 9328226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study.
    Funasaki T; Tsutsumi M; Takase S; Tsuchishima M; Ueshima Y; Urashima S; Shimanaka K; Itoh T; Kawahara H
    Am J Gastroenterol; 1999 Sep; 94(9):2475-81. PubMed ID: 10484011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.
    Tsunoda T; Shibahara H; Hirano Y; Suzuki T; Fujiwara H; Takamizawa S; Ogawa S; Motoyama M; Suzuki M
    Gynecol Endocrinol; 2003 Aug; 17(4):281-6. PubMed ID: 14503971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of dopexamine after cardiac surgery: acute and long-term effects in patients with impaired cardiac function.
    Friedel N; Wenzel R; Matheis G; Hetzer R
    Thorac Cardiovasc Surg; 1992 Dec; 40(6):378-81. PubMed ID: 1363257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentration and acute clinical effects of docarpamine, orally active dopamine prodrug, in infants.
    Tomita H; Fuse S; Chiba S
    Acta Paediatr Jpn; 1996 Oct; 38(5):440-3. PubMed ID: 8942000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of levosimendan in cardiac surgery.
    Aksun M; Karahan N; Adanir T; Aran G; Yetkin U; Oztürk T; Sencan A; Ozgürbüz U; Gürbüz A
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):223-30. PubMed ID: 19520657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of dopamine prodrug, docarpamine.
    Yoshikawa M; Nishiyama S; Takaiti O
    Hypertens Res; 1995 Jun; 18 Suppl 1():S211-3. PubMed ID: 8529066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs.
    Nishiyama S; Kanno K; Yamaguchi I
    J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New avenues in therapy of postoperative low output syndrome].
    el-Banayosy A; Döring B; Körner MM; Posival H; Körtke H; Hartmann D; Körfer R
    Z Kardiol; 1994; 83 Suppl 2():69-74. PubMed ID: 8091827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recurrent low output syndrome after the weaning from mechanical circulatory support for postcardiotomy cardiogenic shock].
    Kamada M; Watanabe S; Fukuju T; Tsuru Y; Akimoto H; Iguchi A; Tabayashi K; Yokoyama H; Ohmi M
    Kyobu Geka; 2002 May; 55(5):389-93. PubMed ID: 11995321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological correction of low cardiac output syndrome in hemofiltration].
    Nikiforov IuV; Lebedeva RN
    Anesteziol Reanimatol; 1997; (3):87-9. PubMed ID: 9289999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Catecholamines in the treatment of the low cardiac output syndrome following heart surgery with extracorporeal circulation].
    Fleischhammer C; Bunge HJ
    Anaesthesiol Reanim; 1990; 15(6):358-67. PubMed ID: 2083004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
    Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE; Arlt A; Meissner A; Lins M
    Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma dopamine concentration and effects of low dopamine doses on urinary output after major vascular surgery.
    Pavoni V; Verri M; Ferraro L; Volta CA; Paparella L; Capuzzo M; Pavanelli L; Buccoliero C; Beani L; Alvisi R; Gritti G
    Kidney Int Suppl; 1998 May; 66():S75-80. PubMed ID: 9573579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
    Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
    Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
    De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
    Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.